Ceragenix to Present at Rodman & Renshaw Third Annual Global Healthcare Conference.DENVER -- Ceragenix Pharmaceuticals, Inc. ("Ceragenix"), a biopharmaceutical company focused on infectious disease and dermatology, today announced that Steven Porter, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Ceragenix, will present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on Monday, May 15 at 11:15 AM UTC (Coordinated Universal Time, Temps Universel Coordonné) The international time standard (formerly Greenwich Mean Time, or GMT). Zero hours UTC is midnight in Greenwich, England, which is located at 0 degrees longitude. (5:15 AM EST EST electroshock therapy. EST abbr. electroshock therapy ) in the Zephyr Zephyr or Zephyrus: see Eos. Salon of the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. The presentation will be web cast and available at http://wsw.com/webcast/rrshq8/cgxp.ob/ . The web cast will be archived until August 15, 2006. Mr. Porter will provide a brief corporate overview and discuss the company's novel anti-infective drugs--based on its proprietary class of compounds, Ceragenins (formerly known as CSAs)--and its Barrier Repair Technology. Ceragenix recently received 510K clearance from the U.S. Food and Drug Administration for its EpiCeram(R) Skin Barrier Emulsion to improve dry skin conditions and to relieve and manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis irritant contact dermatitis Occupational dermatology A form of CD that usually affects the hands and arms, caused by acids, alkalis; the intensity of skin response reflects intrinsic nature of the chemical, its concentration, and duration of contact Clinical , radiation dermatitis, and other dry skin conditions by maintaining a moist wound and skin environment. About CERAGENIX Ceragenix Pharmaceuticals, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : CGXP) is a biopharmaceutical company that discovers, develops and commercializes novel anti-infective drugs based on its proprietary class of compounds, Ceragenins (or CSAs). Active against a broad range of gram positive and negative bacteria, these agents are being developed as anti-infective medical device coatings and as therapeutics for antibiotic-resistant organisms. Ceragenix further owns exclusive rights to Barrier Repair Technology for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenix's patented Barrier Repair Technology, invented by Dr. Peter Elias and licensed from the Regents of the University of California The Regents of the University of California make up the governing board of the University of California. The Board has 26 full (i.e., voting) members:
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion